Compare AstraZeneca plc (AZN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Vanguard Short Term Corporate Bond ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: AstraZeneca plc pays a 2.01% dividend while Vanguard Short Term Corporate Bond ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AZN | VCSH | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Fixed Income |
52-Week High | $209.48 | $80.20 |
52-Week Low | $147.06 | $78.41 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
VCSH trades at $78.59 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with all moving averages signaling sell, though oscillators remain neutral. The ETF maintains a 4.8% yield but faces headwinds from tight credit spreads and an unattractive entry point according to recent analysis. Recent institutional activity shows mixed sentiment with both position increases and decreases.
The outlook remains cautious with limited upside potential due to current rate environment and credit spread compression. Key risks include interest rate sensitivity and competitive pressure from treasury-focused alternatives. Investors seeking short-term corporate bond exposure should monitor credit quality and duration management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
